Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

Trial Profile

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Simvastatin (Primary) ; Zoledronic acid (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 21 Nov 2016 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2016.
    • 21 Nov 2016 Status changed from recruiting to discontinued because Principal Investigator left institution and thus study not continued.
    • 30 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top